Fresenius Helios recently opened a 130-bed building at the company’s hospital in Dachau, a city near Munich. The new structure is part of a €55 million renovation and expansion program that will include a modernization of the existing hospital building over the next two years. Meanwhile, in the northern German city of Nienburg/Weser, work has started on a building that will almost double the size of the emergency department at Fresenius Hospital Mittelweser. About €2.3 million is being invested in this project, which is scheduled for completion in the autumn.
Fresenius Helios has presented the new Helios Science Prize for outstanding research by employees that contributes to improved treatment quality. The three winners all work at hospitals in Germany and were honored for their work in different areas of medicine. The prize, which comes with a cash award, went to Dr. Jitka Veldema of Helios Hospital Kipfenberg (for her work on stroke rehabilitation), Prof. Dr. Alexander Kreuter of Helios St. Elisabeth Hospital in Oberhausen (cancer diagnosis in HIV patients), and Dr. Patrick Weil of Helios University Hospital in Wuppertal (testicular cancer therapy).
Standard & Poor’s has revised Fresenius’ corporate credit outlook to positive from stable in late December 2017. The corporate credit rating was affirmed. Hence, Fresenius is now rated BBB- with positive outlook by Standard & Poor’s. Fresenius is rated investment grade by all of the three leading rating agencies Standard & Poor’s, Moody's and Fitch.
VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2017” at the World Spa Awards. Three VAMED Vitality World facilities – St. Martins Thermal Spa & Lodge and Thermal Spa Laa Hotel & Spa, both in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, will build a hospital in the city of Alcalá de Henares, just outside of Madrid. The approximately 11,000-square-meter (118,000-square-foot) facility will include 106 beds, four operating rooms and two delivery rooms. Quirónsalud will invest about €27 million in the new hospital. It is scheduled to open in 2019.
Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.
Fresenius Vamed has acquired a rehabilitation clinic in Switzerland, its third in the country. The clinic in Seewis has about 75 beds and specializes in heart disease, internal medicine and psychosomatic illnesses. Fresenius Vamed is now active in all major areas of rehabilitative medicine in Switzerland, with a clinic in Zihlschlacht that specializes in neurology and one in Dussnang specializing in orthopedics and geriatrics.
Fresenius Vamed has opened the Institute for Gender Medicine in cooperation with the Medical University of Vienna. This new research institute, in the Lower Austria town of Gars am Kamp, will focus on the different needs of female and male patients, for example in the interpretation of disease symptoms. Fresenius Vamed will be able to use the institute’s research findings to develop tailored treatment offerings in areas such as prevention and rehabilitation. The Institute for Gender Medicine complements initiatives for individualized medical care already being carried out by the VAMED International Medical Board and its approximately 650 physicians.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is undertaking a major expansion of University Hospital Quirónsalud Madrid. A new, 6,000-square-meter (almost 65,000-square-foot) wing scheduled for completion by next summer will add 52 new beds, bringing the hospital’s total to 288. The expansion will also include 25 doctors’ offices, nine resuscitation rooms and three delivery rooms, as well as two hybrid operating rooms that can be used both for conventional operations and for minimally invasive surgical procedures – so-called “keyhole surgery.” All expansion and modernization measures should be completed by the end of 2018. The total investment is about €31 million.
The price increase for hospital services in Germany has been set at 2.97% for 2018. This is in line with the level of past years.
Fresenius Medical Care has expanded its regional manufacturing plant in Bandar Enstek, Malaysia. Dato' Seri Dr. Chen Chaw Min, Secretary General of the Malaysian Ministry of Health graced the opening ceremony. The plant is a state-of-the-art facility and will be Fresenius Medical Care's regional manufacturing hub for Southeast Asia. In addition to supplying high-quality hemodialysis concentrates and disinfectants, the plant produces peritoneal dialysis (PD) products necessary for advanced continuous ambulatory PD treatment.
The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.
Annual Report 2016 (US-GAAP) (PDF, 2.89 MB)
Fresenius "At a Glance" (PDF, 344 KB)
Book "100 Years of Fresenius" (PDF, 6.25 MB)
Fresenius Factsheet FY/2017 (PDF, 435 KB)
Fresenius Medical Care "Profile" (PDF, 368 KB)
Fresenius Medical Care Magazine "Living Knowledge" (PDF, 2.66 MB)
Social Media Guidelines (PDF, 1.97 MB)
Investor Relations General Presentation (PDF, 833 KB)